

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
03 AUG 14 PM 1:01

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name			
Amgen Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported			
1300 Eye Street, NW; Suite 470 East			
3. Principal Place of Business (if different from line 2)			
City: Washington	State/Zip (or Country) DC	20005	
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
L. Nicole Antorcha	202/354-6112	nickiea@amgen.com	3867-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
			31560000

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> \$</p> <p>Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> \$ <u>1,300,000</u></p> <p>Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions of Revenue Code</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Revenue Code</p>

Signature *L. Nicole Antorcha* Date 8/14/03

Printed Name and Title L. Nicole Antorcha Manager of Federal Government Relations Page 1 of

Registrant Name Amgen Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit; Medicare Reimbursement
 Implementation of Section 1833(t)(6) of the Social Security Act
 Reimportation of Pharmaceuticals

H.R. 1: Medicare Prescription Drug and Modernization Act of 2003

S. 1: Prescription Drug and Medicare Improvement Act of 2003

H.R. 980, S.465: Access to Innovation for Medicare Patients Act

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate
 Centers for Medicare and Medicaid Services
 Department of Health and Human Services
 Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
Judi A. Teske	
Andrew Swire	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature



Signature *L. Antorcha* Date 07/17/09

Printed Name and Title L. Nicole Antorcha Manager of Federal Government Relations P

Registrant Name Amgen Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit; Medicare Reimbursement

Implementation of Section 1833(t)(6) of the Social Security Act

AWP Reform

Hospital Outpatient Prospective Payment System (OPPS)

H.R. 1: Medicare Prescription Drug and Modernization Act of 2003

S. 1: Prescription Drug and Medicare Improvement Act of 2003

H.R. 980, S.465: Access to Innovation for Medicare Patients Act

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

U.S. Senate

Centers for Medicare and Medicaid Services

Department of Health and Human Services

Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
Judi A. Teske	
Andrew Swire	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *L. Nicole Antorcha*

Date 8/14/03

Printed Name and Title L. Nicole Antorcha Manager of Federal Government Relations

Page 3

Registrant Name Amgen Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Corporate Tax Provisions

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *L. Nicole Antorcha* Date 8/14/03

Registrant Name Amgen Client Name _____

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

PAT

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution For lobbying activities	Owner: percenta client

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

Signature *L. Nicole Antner* Date 8/14/02

